
Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million

I'm PortAI, I can summarize articles.
Evaxion Biotech announced a new ADS offering to raise $45.5 million, filing a prospectus with the SEC. This move aims to strengthen its capital and market position in the biotechnology sector. The latest analyst rating for EVAX stock is a Buy with a $16.00 price target, though Spark rates it as Neutral due to financial challenges. Evaxion focuses on developing vaccines and immunotherapies using AI technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

